Furthermore, it has been shown that ET-1/ETAR is implicated in EMT in ovarian cancer, and targeting ETAR in combination with chemotherapy can sensitize tumor to chemotherapeutics by preventing EMT-associated signaling [29, 30]. The gene discussed is EDN1; the disease is ovarian carcinoma.